Landmark TIOSPIRTM trial reinforces importance of SPIRIVA® in both available formulations as the world’s leading maintenance therapy for chronic obstructive pulmonary disease (COPD)
TIOSPIR™, with over 17,000 COPD patients included and one of…
9 September 2013 | By Boehringer Ingelheim
TIOSPIR™, with over 17,000 COPD patients included and one of the largest international COPD trials ever conducted...